Alaunos Therapeutics (TCRT) FCF Margin (2011 - 2025)
Alaunos Therapeutics' (TCRT) quarterly FCF Margin came in at 18433.33% in Q4 2025, down 363333.0% YoY from N/an in Q4 2024, and up 52.25% on a QoQ basis from 38600.0% in Q1 2025.
Alaunos Therapeutics (TCRT) FCF Margin (2011 - 2025) Analysis & Trends
Alaunos Therapeutics (TCRT) has 13 years of FCF Margin data on file, last reported at 18433.33% in Q4 2025.
- Quarterly FCF Margin fell 363333.0% year-over-year to 18433.33% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 104300.0% (down 6604000.0% YoY) and the FY2025 annual result came in at 59340.0%, down 963000.0% from the prior year.
- FCF Margin grew to 18433.33% in Q4 2025, from 38600.0% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 66836.36% in Q4 2022 to a low of 905050.0% in Q4 2021.
- A 5-year average of 187501.65% and a median of 38600.0% in 2025 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin surged 97188636 bps — and 2023, when it slumped 80533636 bps.
- Tracing TCRT's FCF Margin over 5 years: stood at 905050.0% in 2021, then jumped by 107 bps to 66836.36% in 2022, then sank by 1205 bps to 738500.0% in 2023, then surged by 98 bps to 14800.0% in 2024, then dropped by 25 bps to 18433.33% in 2025.
- The last three FCF Margin figures came in at 18433.33% (Q4 2025), 38600.0% (Q1 2025), and 14800.0% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 70.82% |
| 10 | Alaunos Therapeutics | 4.26 Mn | 4.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18,433.33% |
| Mar 31, 2025 | -38,600.00% |
| Dec 31, 2024 | -14,800.00% |
| Jun 30, 2024 | -42,025.00% |
| Mar 31, 2024 | -191,700.00% |
| Dec 31, 2023 | -738,500.00% |
| Jun 30, 2023 | -177,425.00% |
| Dec 31, 2022 | 66,836.36% |
| Sep 30, 2022 | -203.64% |
| Dec 31, 2021 | -905,050.00% |
| Sep 30, 2021 | -2,617.59% |
| Mar 31, 2018 | -13,086.99% |
| Dec 31, 2017 | -778.46% |
| Sep 30, 2017 | -800.31% |
| Jun 30, 2017 | -973.70% |
| Mar 31, 2017 | -916.41% |
| Dec 31, 2016 | -823.17% |
| Sep 30, 2016 | -912.33% |
| Jun 30, 2016 | -878.90% |
| Mar 31, 2016 | -824.58% |